Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 6,520 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Recruiting Phase 2 Interventional

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

NCT06083844
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, Bevacizumab, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

NCT04304534
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
BAY2433334, BAY2433334 matching placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
1,601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Boynton Beach, Florida • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Not applicable Interventional

L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer

NCT01155609
View directory record Official record
Conditions
Mucositis, Oral Complications of Chemotherapy, Oral Complications of Radiation Therapy, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Basal Cell Carcinoma of the Lip, Stage II Lymphoepithelioma of the Nasopharynx, Stage II Lymphoepithelioma of the Oropharynx, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
quality-of-life assessment, management of therapy complications, L-lysine
Procedure · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors

NCT00628732
View directory record Official record
Conditions
Solid Tumors
Interventions
Cyclophosphamide and Topotecan
Drug
Lead sponsor
Children's Medical Center Dallas
Other
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

NCT05630001
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

NCT00796965
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

NCT07222709
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1042, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

NCT04878432
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863
View directory record Official record
Conditions
Healthy
Interventions
PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids

NCT00218101
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
25 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT03090412
View directory record Official record
Conditions
Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Interventions
HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

NCT02852265
View directory record Official record
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 29, 2026, 9:58 AM EDT
Recruiting No phase listed Observational

Study of Oral Food Challenge Biomarkers (SAFER)

NCT07279467
View directory record Official record
Conditions
Allergy
Interventions
Oral Food Challenge (OFC): Peanut Protein
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 9:58 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of an Oral Withania Somnifera Product in Older Adults

NCT07008300
View directory record Official record
Conditions
Healthy, Aging
Interventions
Shoden
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 9:58 AM EDT
Completed No phase listed Observational

Rescue FMT with Bezlotoxumab for Recurrent C. Difficile Infection

NCT06669936
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
Fecal microbiota transplantation ± bezlotoxumab
Drug
Lead sponsor
Alexander Khoruts
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT03848832
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

dnaJ Peptide for Relieving Rheumatoid Arthritis

NCT00000435
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
dnaJ peptide, None-placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
8
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2007 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Not applicable Interventional

The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS

NCT00000717
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Primaquine, Clindamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 29, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer

NCT00003489
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
16 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 29, 2026, 9:58 AM EDT
Terminated Not applicable Interventional Results available

Enoxaparin and/or Minocycline in Acute Stroke

NCT00836355
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin, Minocycline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 29, 2026, 9:58 AM EDT